Tyrphostins Reduce Chemotherapy-Induced Intestinal Injury in Mice
Author Information
Author(s): Y Zlotnik, M Patya, A Vanichkin, A Novogrodsky
Primary Institution: Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Rabin Medical Center, Beilinson Campus, Petah-Tikva, Israel
Hypothesis
Can tyrphostins reduce chemotherapy-induced intestinal injury in mice?
Conclusion
The study found that tyrphostins AG1714 and AG1801 effectively prevent chemotherapy-induced intestinal damage in mice.
Supporting Evidence
- Tyrphostins AG1714 and AG1801 significantly reduced intestinal mucosal damage caused by cisplatin and 5-FU in mice.
- The protective effect of AG1714 was previously reported without impairing its antitumor efficacy.
- Oral administration of tyrphostins was found to be more effective than intraperitoneal administration.
Takeaway
This study shows that certain drugs can help protect mice from stomach problems caused by cancer treatments.
Methodology
Mice were treated with tyrphostins before chemotherapy, and intestinal injury was assessed using a biochemical assay measuring gamma-glutamyl transpeptidase activity.
Limitations
The study was limited to acute small intestinal injury and may not apply to other types of intestinal damage.
Participant Demographics
CD1 female mice, weighing 20–25 g.
Statistical Information
P-Value
<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website